FDA INVESTIGATION HAS LED TO CHARGES AGAINST TWO INDIAN NATIONALS INVOLVED IN A TRANSNATIONAL COUNTERFEIT DRUG DISTRIBUTION SCHEME, WITH THE FDA ALLEGING THAT BETWEEN JULY 2023 AND APRIL 2024, SWAPNADIP ROY AND VICKY RAMANCHA OBTAINED COUNTERFEIT OZEMPIC FROM UNAUTHORIZED SOURCES IN CHINA
FDA INVESTIGATION HAS LED TO CHARGES AGAINST TWO INDIAN NATIONALS INVOLVED IN A TRANSNATIONAL COUNTERFEIT DRUG DISTRIBUTION SCHEME, WITH THE FDA ALLEGING THAT BETWEEN JULY 2023 AND APRIL 2024, SWAPNADIP ROY AND VICKY RAMANCHA OBTAINED COUNTERFEIT OZEMPIC FROM UNAUTHORIZED SOURCES IN CHINA
FDA Panel to Review GRAIL’s Galleri Cancer Blood Test
FDA staff found no major concerns with GRAIL’s Galleri multicancer blood test ahead of a September 23 advisory committee review
FDA Updates Regulations to Advance Innovative Alternatives to Animal Testing
New rule supports wider use of innovative testing methods while maintaining existing safety standards for human drug development
FDA approves Eli Lilly’s $LLY Inluriyo + Verzenio for a form of advanced breast cancer driven by the ESR1 mutation.
The treatment is for adults with ER-positive, HER2-negative advanced or metastatic disease and is now available in the U.S.